Description
LuciApro 12.5 MG (Aprocitentan) is a dual endothelin receptor antagonist (dual ETA and ETB receptor antagonist) an orally bioavailable, small-molecule targeted agent that blocks endothelin-1 (ET-1)-mediated vasoconstriction and renal sodium retention driving uncontrolled blood pressure in resistant hypertension supplied as tablets in 12.5 mg strength in a 30-tablet pack and manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos. Its active ingredient, aprocitentan INN, simultaneously antagonises both endothelin type-A (ETA) receptors on vascular smooth muscle cells and endothelin type-B (ETB) receptors on renal collecting duct epithelium, addressing two distinct ET-1-mediated pathological mechanisms sustained peripheral vasoconstriction and renal sodium retention that together sustain elevated blood pressure in patients whose hypertension fails to respond to three or more antihypertensive agents.
In the landmark Phase 3 PRECISION trial (730 patients with resistant hypertension on standardised triple background therapy published in The Lancet, 2023), aprocitentan 12.5 mg once daily achieved a placebo-corrected reduction in seated systolic blood pressure (SBP) of −3.8 mmHg at week 12 (95% CI −6.3 to −1.4; p=0.0042), with sustained blood pressure lowering confirmed in the 40-week withdrawal phase, where patients who discontinued aprocitentan experienced a mean SBP rebound of approximately 5.8 mmHg versus those who continued treatment. Aprocitentan (Tryvio®) received United States Food and Drug Administration (FDA) approval in March 2024, becoming the first drug with a new mechanism of action approved for resistant hypertension in more than a decade. Searching for LuciApro 12.5 MG Aprocitentan? Mediaid Pharmacy lists this product across its cardiovascular medicines, hypertension medicines, and Lucius Pharmaceuticals portfolios and ships it worldwide.
Basic Product Information of LuciApro 12.5 MG (Aprocitentan)
| Brand Name | LuciApro 12.5 MG (Aprocitentan) |
| Product Name | LuciApro |
| Generic Name | Aprocitentan INN |
| Drug Class | Dual Endothelin Receptor Antagonist (Dual ETA and ETB Receptor Antagonist); Endothelin Receptor Antagonist (ERA); Resistant Hypertension Agent; Cardiovascular Agent; Antihypertensive Agent; Novel Mechanism Antihypertensive |
| Formulation | Tablet (Oral) |
| Available Strengths | 12.5 mg per tablet |
| Available Pack Size | 30 Tablets per Pack |
| Dosing & Dose Modification | Approved dose: 12.5 mg once daily, orally, with or without food, taken in combination with other antihypertensive medications. LuciApro (Aprocitentan) is not indicated for monotherapy and must always be prescribed as add-on therapy to an existing antihypertensive regimen in patients with resistant hypertension. No dose titration: 12.5 mg once daily is the single approved dose there is no approved dose escalation beyond 12.5 mg in the resistant hypertension indication. Strong CYP3A4 inducers: Avoid concomitant use with strong CYP3A4 inducers such as rifampin, as these reduce aprocitentan exposure by approximately 57% and may substantially reduce antihypertensive efficacy. Swallow LuciApro tablets whole do not crush, split, or chew. |
| Primary Indications | Hypertension to lower blood pressure in combination with other antihypertensive medications, in adult patients with resistant hypertension (hypertension that remains uncontrolled despite concurrent use of three or more antihypertensive agents, including a diuretic). LuciApro (Aprocitentan) is not indicated as monotherapy, for first-line hypertension treatment, or for pulmonary arterial hypertension (PAH). Each treatment decision must account for renal function, concurrent antihypertensive regimen, reproductive status, and fluid balance always consult the full prescribing information and the treating cardiologist or hypertension specialist. |
| Manufacturer | Lucius Pharmaceuticals (Lao) Co., Ltd., Laos |
| Country of Origin | Laos |
| Originator Reference Brand | Tryvio® (aprocitentan 12.5 mg tablets, developed by Idorsia Pharmaceuticals Ltd. and commercialised in collaboration with Janssen Pharmaceuticals, a Johnson & Johnson company FDA-approved in the United States, March 2024). Tryvio® contains aprocitentan INN as the active pharmaceutical ingredient in the same dual ETA and ETB endothelin receptor antagonist drug class. LuciApro is manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos and is supplied through Mediaid Pharmacy for international procurement. |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
| Storage Conditions | Store at room temperature (15°C to 30°C). Keep in the original packaging and protect from moisture. Keep out of the reach of children. |
How LuciApro (Aprocitentan) Works: Dual Endothelin ETA and ETB Receptor Blockade in Resistant Hypertension
Aprocitentan INN is an orally bioavailable, sulfonamide-class, small-molecule antagonist that simultaneously blocks both endothelin type-A (ETA) and endothelin type-B (ETB) receptors the two G-protein-coupled receptor subtypes through which endothelin-1 (ET-1) drives its vascular and renal effects with near-balanced potency, characterised by an ETA inhibitory constant (Ki) of 1.6 nM and an ETB Ki of 1.1 nM. ET-1 is a 21-amino acid vasoactive peptide produced primarily by vascular endothelial cells and is one of the most potent endogenous vasoconstrictors in human physiology. In the peripheral vasculature, ET-1 acts via ETA receptors located on vascular smooth muscle cells to drive sustained, prolonged vasoconstriction and vascular smooth muscle hypertrophy effects particularly relevant to systemic hypertension because ET-1-induced peripheral vascular resistance elevations are long-lasting and poorly reversed by standard renin-angiotensin-aldosterone system (RAAS) inhibition or calcium channel blockade.
In the kidney, ET-1 acts via ETB receptors located on collecting duct principal cells to promote sodium reabsorption and water retention, further increasing plasma volume and blood pressure a mechanism that explains why endothelin pathway activation is a major contributor to salt-sensitive and aldosterone-independent volume-dependent hypertension. In resistant hypertension defined as blood pressure that remains uncontrolled despite concurrent use of three or more antihypertensive agents including a diuretic circulating and endothelial ET-1 activity is often disproportionately elevated, contributing to a pathophysiological state that is mechanistically distinct from and inadequately addressed by dose-escalation or regimen-intensification using existing drug classes.
By simultaneously antagonising both ETA-mediated peripheral vasoconstriction and ETB-mediated renal sodium retention, aprocitentan delivers dual-mechanism antihypertensive action that complements rather than overlaps with the mechanisms of standard background antihypertensives angiotensin receptor blockers (ARBs), calcium channel blockers (CCBs), and thiazide diuretics providing incremental blood pressure reduction on top of maximal conventional therapy. This dual ETA+ETB blockade pharmacology distinguishes aprocitentan from selective ETA-only antagonists such as ambrisentan (used in pulmonary arterial hypertension), where ETB preservation is prioritised to maintain ETB-mediated ET-1 clearance and pulmonary endothelial nitric oxide production; in systemic resistant hypertension, the additional ETB blockade of renal sodium retention is a therapeutically beneficial, mechanistically additive effect.
The clinical consequence of dual ETA and ETB blockade in resistant hypertension is an additive reduction in both peripheral vascular resistance and renal sodium retention, generating incremental systolic and diastolic blood pressure lowering on top of triple-drug background antihypertensive therapy a clinically meaningful outcome for a patient population in whom conventional dose escalation and regimen intensification have already been maximised. The PRECISION Phase 3 trial confirmed that aprocitentan 12.5 mg once daily produced statistically significant placebo-corrected SBP reductions of −3.8 mmHg at week 12 (p=0.0042), and that the antihypertensive effect is sustained, as demonstrated by the 40-week withdrawal phase in which patients switched to placebo experienced SBP rebound of approximately 5.8 mmHg relative to those who continued aprocitentan.
Pharmacokinetically, aprocitentan exhibits dose-proportional pharmacokinetics with a mean terminal elimination half-life (t½) of approximately 16 to 17 hours, supporting reliable once-daily oral dosing without appreciable plasma level fluctuation between doses. Aprocitentan is primarily metabolised by cytochrome P450 3A4 (CYP3A4) and CYP2C8 enzymes and undergoes hepatic glucuronidation; co-administration with potent CYP3A4 inducers such as rifampin substantially reduces aprocitentan plasma exposure (by approximately 57% in area under the plasma concentration-time curve [AUC]) and concurrent use should be avoided.
Aprocitentan is not a clinically significant inhibitor of major CYP or UGT enzymes at the approved 12.5 mg dose, limiting the risk of pharmacokinetic drug–drug interactions with co-administered antihypertensives. Edema and fluid retention are the primary class-effect adverse reaction of endothelin receptor antagonism across both ETA-selective and dual ERA agents and reflect ETB blockade in the renal collecting duct reducing ETB-mediated natriuresis; monitoring fluid balance and body weight is standard clinical practice during aprocitentan treatment. For the complete range of cardiovascular and hypertension medicines available at Mediaid Pharmacy, visit the cardiovascular medicines collection.
LuciApro 12.5 MG (Aprocitentan): Indications, Dosing, and Key Safety Information
| Approved Indication | Resistant Hypertension: Treatment of hypertension, to lower blood pressure, in combination with other antihypertensive medications, in adult patients with resistant hypertension defined as blood pressure that is uncontrolled despite concurrent use of three or more antihypertensive agents including a diuretic, all prescribed at optimised doses. LuciApro (Aprocitentan) is indicated as add-on therapy only, not as monotherapy or first-line antihypertensive treatment. |
| Recommended Dose | Resistant hypertension (add-on therapy): 12.5 mg once daily orally, with or without food (1× LuciApro 12.5 MG tablet once daily), administered in combination with the patient’s existing antihypertensive regimen. No dose escalation: 12.5 mg once daily is the single approved dose for resistant hypertension do not increase beyond 12.5 mg. Strong CYP3A4 inducers: Avoid co-administration with strong CYP3A4 inducers (e.g., rifampin) as these reduce aprocitentan plasma exposure by approximately 57%, likely abolishing antihypertensive efficacy. Swallow LuciApro tablets whole do not crush, split, or chew. |
| Dose Titration & Modification | Aprocitentan does not have an approved dose titration scheme; 12.5 mg once daily is the single approved antihypertensive dose (the PRECISION trial studied both 12.5 mg and 25 mg, with comparable blood pressure lowering between doses and more fluid retention at 25 mg, supporting 12.5 mg as the optimal dose). Dose reduction or discontinuation may be required for: confirmed pregnancy (contraindicated must be discontinued immediately); clinically significant hepatic aminotransferase elevations (>3× upper limit of normal [ULN]); symptomatic or severe fluid retention or peripheral oedema not manageable with diuretic optimisation; or known hypersensitivity to aprocitentan or any excipient. Avoid concomitant use with strong CYP3A4 inducers throughout treatment. |
| Missed Dose | If a dose of LuciApro (Aprocitentan) is missed, take it as soon as remembered on the same day. If not remembered until the following day, skip the missed dose and resume with the next scheduled once-daily dose. Do not take two doses within the same 24-hour period to make up for a missed dose. Take LuciApro at the same time each day to maintain consistent plasma concentrations and sustained antihypertensive effect. |
| Key Warnings & Precautions | Embryo-Fetal Toxicity (Contraindicated in Pregnancy): Aprocitentan is contraindicated in pregnancy. Endothelin receptor antagonists are teratogenic ET-1 signalling through ETA receptors is essential for normal cardiovascular and craniofacial development during foetal organogenesis, and blockade during pregnancy may cause major congenital malformations and foetal death. Females of reproductive potential must use two reliable forms of contraception during LuciApro treatment and for at least one month after the final dose. Perform a pregnancy test before initiating LuciApro and monthly during treatment. Breastfeeding is not recommended during LuciApro treatment.
Fluid Retention and Peripheral Oedema: Fluid retention and peripheral oedema are the most common adverse reactions of aprocitentan, occurring in approximately 9.9% of patients at 12.5 mg in the PRECISION trial versus 2.5% with placebo. Monitor body weight and fluid status at baseline and regularly throughout treatment. Clinically significant fluid retention may require intensification of background diuretic therapy, dose reduction, or LuciApro discontinuation. Hepatotoxicity: Hepatic aminotransferase elevations (ALT and AST) have been reported with endothelin receptor antagonist class agents. Monitor liver function tests (LFTs) at baseline and periodically during LuciApro treatment. Discontinue LuciApro if aminotransferases exceed 5× ULN or if clinical signs of hepatic injury are present (jaundice, right upper quadrant pain, fatigue, nausea). Decreased Haemoglobin / Anaemia: Decreases in haemoglobin and haematocrit have been observed with ERA class agents. Assess haemoglobin at baseline and periodically during LuciApro treatment; clinically significant anaemia may require dose modification or treatment interruption. Drug Interaction Strong CYP3A4 Inducers: Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John’s Wort) substantially reduce aprocitentan plasma exposure and should be avoided during LuciApro treatment. Rifampin co-administration reduces aprocitentan AUC by approximately 57%, likely eliminating its antihypertensive benefit. Add-On Therapy Only: LuciApro (Aprocitentan) is not indicated for monotherapy. Prescribing outside the context of concurrent antihypertensive background therapy has not been studied and is not supported by the approved indication. |
| Common Adverse Reactions (≥5%) | Peripheral oedema and fluid retention (9.9% at 12.5 mg versus 2.5% with placebo in PRECISION), nasopharyngitis, headache, and dizziness. Fluid retention is the most clinically significant and most frequent adverse reaction at the approved dose; it reflects dual ETB blockade in the renal collecting duct reducing natriuresis and is manageable in most patients through diuretic optimisation. Hepatic aminotransferase elevations and decreases in haemoglobin are class-effect adverse reactions of ERA agents that require baseline and periodic laboratory monitoring throughout LuciApro treatment. |
| Drug Interactions | Aprocitentan is a substrate of CYP3A4, CYP2C8, and hepatic glucuronidation pathways. Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, efavirenz, St. John’s Wort): rifampin co-administration reduces aprocitentan AUC by approximately 57% avoid concomitant use; similar reductions are expected with other potent inducers. Moderate-to-strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir): may increase aprocitentan plasma exposure; monitor for increased adverse reactions including oedema. CYP2C8 inhibitors (gemfibrozil): may increase aprocitentan exposure; use with caution and monitor. Aprocitentan does not significantly inhibit CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at the approved 12.5 mg dose and is not expected to alter the pharmacokinetics of co-administered antihypertensive agents via CYP inhibition. Disclose all concomitant medications, herbal supplements, and antibiotic or antifungal courses to the treating cardiologist or hypertension specialist before initiating LuciApro. |
| Hepatic Impairment | Aprocitentan has not been fully characterised in patients with moderate to severe hepatic impairment (Child-Pugh Class B or C). Use of LuciApro in patients with clinically significant pre-existing hepatic impairment is not recommended. Monitor liver aminotransferases (ALT, AST) at baseline and periodically throughout treatment. Discontinue LuciApro if serum aminotransferases exceed 5× ULN or if clinical signs of hepatic injury develop. Consult the treating hepatologist, nephrologist, and cardiologist for individualised guidance in patients with hepatic or renal comorbidities. |
| Pregnancy & Lactation | Aprocitentan is contraindicated in pregnancy it is teratogenic and may cause major congenital malformations and foetal death based on its mechanism of action as a dual endothelin receptor antagonist. ET-1 signalling via ETA receptors is critical during foetal cardiovascular and craniofacial organogenesis; dual ETA and ETB blockade during pregnancy poses a serious developmental toxicity risk. Females of reproductive potential must use two reliable, complementary methods of contraception during LuciApro treatment and for at least one month after the final dose. A pregnancy test must be performed before initiating LuciApro and monthly during treatment. Breastfeeding is not recommended during LuciApro treatment and for a clinically appropriate washout period thereafter. If pregnancy occurs during aprocitentan treatment, the treating cardiologist or hypertension specialist must be notified immediately and LuciApro discontinued without delay. |
Who Should Use LuciApro 12.5 MG (Aprocitentan)?
LuciApro 12.5 MG (Aprocitentan) is indicated for adult patients with resistant hypertension a clinically distinct and high-risk hypertension phenotype defined as blood pressure that remains above goal despite concurrent, optimised use of three or more antihypertensive medications from different classes, including a diuretic at maximally tolerated doses. Resistant hypertension affects an estimated 10 to 15% of all treated hypertensive patients and carries substantially elevated cardiovascular event risk, including higher rates of myocardial infarction, stroke, heart failure, and end-stage renal disease compared with controlled hypertension.
The endothelin-1 pathway is disproportionately activated in resistant hypertension relative to well-controlled hypertension, contributing to vasoconstriction and sodium retention that persists despite RAAS blockade, calcium channel blockade, and diuretic therapy making dual ETA and ETB receptor blockade with aprocitentan a mechanistically rational and evidence-based therapeutic addition.
First, adult patients with confirmed resistant hypertension verified by ambulatory blood pressure monitoring (ABPM) or repeated standardised office blood pressure measurement above goal on maximally tolerated triple therapy including an ARB or ACE inhibitor, a dihydropyridine calcium channel blocker, and a thiazide or thiazide-like diuretic are the core indication population for LuciApro (Aprocitentan). In the PRECISION Phase 3 trial, all 730 enrolled patients were converted to a standardised triple background regimen (olmesartan 40 mg, amlodipine 10 mg, and hydrochlorothiazide 25 mg) during the four-week single-blind run-in phase before randomisation, confirming that both background therapy optimisation and residual BP elevation co-existed before aprocitentan was added, establishing the genuine add-on benefit of the endothelin receptor antagonist mechanism in this population.
Second, patients with apparent treatment-resistant hypertension must be differentiated from those with pseudoresistance nonadherence to prescribed medications, white-coat effect, or suboptimal diuretic choice before initiating LuciApro; ABPM and pill counts or pharmacy fill records are standard tools for confirming true resistance prior to treatment escalation with a novel mechanism agent.
Third, patients with comorbid obstructive sleep apnoea (OSA)-associated resistant hypertension may be a particularly relevant subgroup for aprocitentan, as OSA-driven sympathetic activation and aldosterone dysregulation amplify ET-1 pathway activity and contribute to OSA-related treatment-resistant blood pressure elevation, a mechanistic basis consistent with the patient population enrolled in PRECISION. LuciApro is contraindicated in pregnancy, in patients with moderate to severe hepatic impairment, and in patients with known hypersensitivity to aprocitentan or any excipient. Concomitant use with strong CYP3A4 inducers (rifampin and analogues) must be avoided. The treating cardiologist or hypertension specialist must confirm resistant hypertension by ABPM, review all concomitant medications for drug–drug interactions with CYP3A4 inducers, assess baseline haemoglobin, liver function, and reproductive status, and establish a monitoring schedule for fluid retention before initiating LuciApro.
Cardiology and hypertension centres co-sourcing LuciApro alongside complementary cardiovascular agents can browse the Mediaid Pharmacy hypertension medicines and cardiovascular medicines portfolios for the full selection available for international delivery.
Global Supplier: Mediaid Pharmacy Worldwide Shipping for LuciApro 12.5 MG (Aprocitentan)
Mediaid Pharmacy is a Dhaka-based supplier of specialty cardiovascular and antihypertensive medicines with worldwide shipping to patients, hypertension clinics, cardiology centres, nephrology programmes, and international distributors across all regions. LuciApro 12.5 MG (Aprocitentan), manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos, is supplied as 30 tablets per pack in 12.5 mg strength with pricing quotations, stock confirmation, full product documentation, and end-to-end international delivery tracking for every order. The 12.5 mg strength is the single approved antihypertensive dose of aprocitentan for resistant hypertension, enabling hypertension programmes and cardiology centres to implement add-on dual endothelin receptor blockade without dose titration complexity from a single supplier relationship.
Hypertension centres, cardiology programmes managing high-cardiovascular-risk patients with resistant blood pressure, nephrology units treating CKD-associated resistant hypertension, international distributors, and individual patients can contact the Mediaid Pharmacy team through WhatsApp, phone, or WeChat for all inquiries regarding LuciApro Aprocitentan stock availability, current pricing, and international delivery timelines to their country. Procurement teams co-sourcing LuciApro with other cardiovascular or antihypertensive agents can browse the complete Mediaid Pharmacy cardiovascular medicines collection and the Lucius Pharmaceuticals medicines portfolio before requesting a consolidated quotation.
Why Choose LuciApro 12.5 MG (Aprocitentan) from Mediaid Pharmacy?
LuciApro 12.5 MG (Aprocitentan) provides cardiologists, hypertension specialists, and nephrologists with the first new mechanistic class approved for resistant hypertension in more than a decade a dual ETA and ETB endothelin receptor antagonist backed by the Phase 3 PRECISION trial, published in The Lancet (2023), that demonstrated statistically significant and sustained blood pressure reduction in a rigorously standardised resistant hypertension population. The PRECISION trial (730 patients) mandated a four-week single-blind run-in phase in which all participants received standardised triple background therapy (olmesartan 40 mg + amlodipine 10 mg + hydrochlorothiazide 25 mg) to confirm true resistance before randomisation a design feature that strengthens the internal validity of the trial results by eliminating pseudoresistance from the enrolled population.
Aprocitentan 12.5 mg once daily achieved a placebo-corrected seated SBP reduction of −3.8 mmHg at week 12 (95% CI −6.3 to −1.4; p=0.0042) and a placebo-corrected seated diastolic blood pressure (DBP) reduction of −2.0 mmHg (p=0.0048) on top of triple therapy an effect size clinically relevant in resistant hypertension, where each additional 2 to 3 mmHg reduction in SBP translates to measurable reductions in cardiovascular event rates. The 40-week withdrawal phase of PRECISION provides uniquely robust evidence for the durability and mechanistic specificity of aprocitentan’s antihypertensive effect: patients randomised to placebo after completing the 12-week treatment phase experienced a mean SBP rebound of approximately 5.8 mmHg within weeks of discontinuation, confirming that the blood pressure lowering was attributable to active endothelin receptor blockade rather than regression to the mean or non-specific effects.
Aprocitentan’s dual ETA and ETB pharmacology addresses two mechanistically distinct and additive contributors to resistant hypertension ETA-mediated vasoconstriction and ETB-mediated renal sodium retention providing antihypertensive action that is complementary to and non-overlapping with standard background RAAS inhibition, calcium channel blockade, and diuresis. This mechanistic complementarity is precisely why aprocitentan received FDA approval as add-on therapy for resistant hypertension in March 2024 under the brand name Tryvio®, representing a genuine therapeutic advance for a patient population with high residual cardiovascular risk and limited prior pharmacological options.
LuciApro is manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos and is available through Mediaid Pharmacy with full product documentation, specialist supply coordination, and worldwide shipping from Dhaka. To source additional Lucius Pharmaceuticals cardiovascular medicines, visit the Mediaid Pharmacy Lucius Pharmaceuticals medicines section and the hypertension medicines portfolio, and contact the team for a personalised quotation.
Frequently Asked Questions About LuciApro 12.5 MG (Aprocitentan)
What is LuciApro 12.5 MG (Aprocitentan) used for?
LuciApro 12.5 MG (Aprocitentan) is a dual endothelin ETA and ETB receptor antagonist used for the treatment of hypertension to lower blood pressure in combination with other antihypertensive medications, in adult patients with resistant hypertension (blood pressure uncontrolled on three or more antihypertensive agents including a diuretic). LuciApro is not a monotherapy and must always be prescribed as add-on to an existing antihypertensive regimen. It is not indicated for pulmonary arterial hypertension (PAH). The originator brand for aprocitentan is Tryvio® (Idorsia Pharmaceuticals / Janssen, FDA-approved March 2024). LuciApro, manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos, is available through Mediaid Pharmacy with worldwide shipping to patients, cardiology centres, and hypertension clinics.
What is the generic name of LuciApro?
The generic name of LuciApro is aprocitentan INN. LuciApro is the brand name registered by Lucius Pharmaceuticals (Lao) Co., Ltd. for aprocitentan manufactured in Laos. LuciApro is formulated as oral tablets in 12.5 mg strength, supplied in a 30-tablet pack. The 12.5 mg strength is the single approved dose of aprocitentan for resistant hypertension the same dose studied in the pivotal PRECISION Phase 3 trial that supported FDA approval of Tryvio® in March 2024. Mediaid Pharmacy distributes LuciApro globally with worldwide shipping to patients, hypertension specialists, cardiologists, and nephrology units.
What is the difference between LuciApro (Aprocitentan) and Tryvio (Aprocitentan)?
LuciApro and Tryvio® both contain aprocitentan INN as the active pharmaceutical ingredient and share the same dual ETA and ETB endothelin receptor antagonist mechanism of action in resistant hypertension. Tryvio® is the originator brand developed by Idorsia Pharmaceuticals Ltd. and commercialised by Janssen Pharmaceuticals (Johnson & Johnson) in the United States, where it received FDA approval in March 2024, supplied as 12.5 mg tablets. LuciApro is manufactured by Lucius Pharmaceuticals (Lao) Co., Ltd. in Laos and is supplied in the 12.5 mg strength the single approved antihypertensive dose available through Mediaid Pharmacy for international procurement by specialist centres and patients in regions where Tryvio® may be unavailable or cost-prohibitive. For the full range of hypertension medicines at Mediaid Pharmacy, visit the hypertension medicines collection.
How is LuciApro 12.5 MG (Aprocitentan) administered?
LuciApro (Aprocitentan) is administered orally once daily at the same time each day with or without food, in combination with other antihypertensive medications. The approved dose is 12.5 mg once daily; this is the single approved dose and there is no dose escalation above 12.5 mg for resistant hypertension. Swallow LuciApro tablets whole with water do not crush, split, or chew the tablets. If a dose is missed, take it as soon as remembered on the same day; if not remembered until the next day, skip the missed dose and resume with the next scheduled dose. Do not take two doses in one day. Avoid concomitant use with strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John’s Wort) throughout treatment, as these substantially reduce aprocitentan plasma exposure. Do not discontinue LuciApro without consulting the treating cardiologist or hypertension specialist, as blood pressure may rebound within weeks of stopping treatment, as demonstrated in the PRECISION withdrawal phase.
What are the side effects of LuciApro 12.5 MG (Aprocitentan)?
The most common adverse reaction of LuciApro (Aprocitentan) is peripheral oedema and fluid retention, occurring in approximately 9.9% of patients receiving 12.5 mg once daily in the PRECISION Phase 3 trial versus 2.5% with placebo. Fluid retention reflects the class effect of dual ETB receptor blockade reducing natriuresis in the renal collecting duct and is manageable in most patients through optimisation of background diuretic therapy; severe or symptomatic fluid retention may require LuciApro dose interruption or discontinuation. Other reported adverse reactions include nasopharyngitis, headache, and dizziness. Embryo-fetal toxicity is the most serious safety concern aprocitentan is contraindicated in pregnancy and requires reliable contraception throughout treatment. Hepatic aminotransferase elevations and haemoglobin decreases are class-effect adverse reactions of ERA agents that require monitoring at baseline and periodically during treatment. Always discuss the complete safety profile, fluid monitoring requirements, and contraception obligations with the treating cardiologist or hypertension specialist before and throughout LuciApro treatment.
How effective is Aprocitentan (LuciApro) for resistant hypertension?
Aprocitentan has demonstrated statistically significant and mechanistically confirmed antihypertensive efficacy in resistant hypertension in the Phase 3 PRECISION trial, published in The Lancet in 2023. The trial enrolled 730 patients with confirmed resistant hypertension who were standardised onto triple background therapy (olmesartan 40 mg + amlodipine 10 mg + hydrochlorothiazide 25 mg) for four weeks before randomisation. At week 12, aprocitentan 12.5 mg once daily produced a placebo-corrected reduction in seated systolic blood pressure of −3.8 mmHg (95% CI −6.3 to −1.4; p=0.0042) and a placebo-corrected diastolic BP reduction of −2.0 mmHg (p=0.0048), both on top of standardised triple therapy. The durability of blood pressure lowering was confirmed in the 40-week withdrawal phase, where patients who switched from aprocitentan to placebo experienced a mean SBP rebound of approximately 5.8 mmHg a statistically and clinically significant increase demonstrating that the blood pressure reductions during the treatment phase were pharmacologically driven and genuinely sustained. LuciApro delivers the same active ingredient aprocitentan INN at the approved 12.5 mg tablet dose, sourced through Mediaid Pharmacy with worldwide shipping. For the complete cardiovascular medicines range at Mediaid Pharmacy, visit the cardiovascular medicines collection.
Is LuciApro 12.5 MG (Aprocitentan) safe during pregnancy or while breastfeeding?
No. Aprocitentan is contraindicated in pregnancy it is teratogenic and may cause major congenital malformations and foetal death. The endothelin receptor system, including both ETA and ETB receptor subtypes, is essential for normal cardiovascular and craniofacial foetal development during organogenesis; blockade of both receptor subtypes during pregnancy poses a serious developmental toxicity risk confirmed in animal reproductive studies, consistent with the known class effect of endothelin receptor antagonists. LuciApro must not be used during pregnancy. Females of reproductive potential must use two reliable, complementary forms of contraception during LuciApro treatment and for at least one month after the final dose. A pregnancy test must be performed before initiating treatment and monthly during treatment. Breastfeeding is not recommended during LuciApro treatment and for a clinically appropriate washout period after the final dose. If pregnancy occurs or is suspected during aprocitentan treatment, the treating cardiologist or hypertension specialist must be notified immediately and LuciApro discontinued without delay. Consult the treating specialist before starting LuciApro in all patients of reproductive potential.
Can I order LuciApro 12.5 MG (Aprocitentan) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies LuciApro 12.5 MG (Aprocitentan) to patients, cardiology centres, hypertension clinics, nephrology units, and healthcare providers globally. Contact Mediaid Pharmacy via WhatsApp, phone, or WeChat at +8801773428128, or email info@mediaidpharmacy.com for pricing, current stock availability, and international delivery details for your country.
Order LuciApro 12.5 MG (Aprocitentan) with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com
Reviews
There are no reviews yet.